David Ellens
Internal Medicine · Clermont, FLNPI 1780785402
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $605 and has fallen 96.4% since, to $21 in 2024.
Across 132 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$432
- Novo Nordisk$265
- Lilly USA, LLC$237
- Boehringer Ingelheim$187
- Pfizer$159
- Bayer$136
- plus $758 from 22 others
What the payments were for
- Food & beverage$2,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $432 |
| Novo Nordisk | 16 | $265 |
| Lilly USA, LLC | 20 | $237 |
| Boehringer Ingelheim | 9 | $187 |
| Pfizer | 9 | $159 |
| Bayer | 2 | $136 |
| Amgen | 8 | $113 |
| AbbVie(2 entities) | 4 | $89 |
| Johnson & Johnson | 3 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| GSK | 3 | $41 |
| Exact Sciences | 2 | $40 |
| Novartis | 2 | $38 |
| Abbott | 2 | $36 |
| CSL Behring | 2 | $31 |
| Cranial Technologies, Inc | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Si-bone, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Bio Products Laboratory USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$123
How this compares
$2,174 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $112,461 |
| OzempicSemaglutide | 102 | $97,776 |
| JardianceEmpagliflozin | 74 | $72,834 |
| TrulicityDulaglutide | 35 | $51,577 |
| TivicayDolutegravir Sodium | 13 | $27,713 |
| FarxigaDapagliflozin Propanediol | 21 | $23,754 |
| MounjaroTirzepatide | 20 | $21,860 |
| LinzessLinaclotide | 26 | $20,561 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $13,607 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,816 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,242 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $7,204 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 244 | $6,583 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,197 |
| Varenicline Tartrate | 14 | $5,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $112,461127 claims |
| Novo NordiskOzempic | $265 | $97,776102 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $187 | $81,07590 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $237 | $73,43755 claims |
| AstraZenecaFarxiga, Symbicort | $432 | $29,95138 claims |
| AbbVieLinzess | $89 | $20,56126 claims |
| GSKTrelegy Ellipta | $41 | $10,81613 claims |
| Sanofi-aventis U.S. LLCLantus | $59 | $1,98428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Clermont
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.